HGH Fragment 176

HGH Fragment 176-191 is a linear 16-residue peptide whose sequence corresponds to the C-terminal segment of the 191-residue human growth hormone polypeptide. Structural details for the supplied lot — sequence, molecular weight, and any post-synthesis modifications — are established through the supplier's Certificate of Analysis. The molecule's interaction profile in the published literature centers on lipolytic-pathway engagement in adipocyte cell-culture investigations, with downstream studies probing fat-metabolism markers and β-adrenergic-pathway intersection. The fragment lacks the receptor-binding determinants of the parent growth hormone responsible for somatotrophic signaling, providing a research material that allows investigators to dissect the lipolytic profile from the broader anabolic profile. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance under standard parenteral paradigms. All activity descriptors here are framed as documented in published research.

Experimental domains documented in the published literature include in-vitro adipocyte lipolysis assays, fat-metabolism-pathway investigations in cell-culture and rodent-model contexts, structure-activity work probing the C-terminal contributions of human growth hormone to lipolytic signaling, comparative work alongside full-length human growth hormone and other GH-fragment research peptides, and screening assays for lipolytic-pathway-active short peptide research. Investigators have also characterized HGH Fragment 176-191 in studies of β-adrenergic-pathway intersection and in cell-culture model systems for fat-cell metabolism research. Use in laboratory research extends to mechanism-elucidation paradigms where the fragment serves as a probe for GH C-terminal-derived lipolytic signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the supplier-COA-specified empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA is the primary citation chain for this reference standard and records the lot identifier, manufacturing date, and analytical method versions used — providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.